MIR1976: A Drug Target / Disease Biomarker (G100302190)
MIR1976: A Drug Target / Disease Biomarker
MIR1976, also known as interleukin-18 (IL-18), is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a cytokine that plays a crucial role in the immune response and has been implicated in a number of diseases, including cancer, fibrosis, and autoimmune disorders.
One of the most promising aspects of MIR1976 is its potential as a drug target. The MIR1976 protein has been shown to interact with a variety of different drugs, including small molecules, antibodies, and nucleic acids. This makes it an attractive target for drug developers because it can be targeted with a wide range of compounds, rather than having to develop specific inhibitors for it.
One of the first drugs to be developed specifically for MIR1976 was a small molecule called ALX01620, which is a potent inhibitor of MIR1976. The drug was shown to be effective in preclinical studies for treating a variety of diseases, including cancer, fibrosis, and autoimmune disorders.
Another drug that is being developed as a potential treatment for MIR1976 is a monoclonal antibody called ADX112201. The antibody is designed to selectively bind to MIR1976 and inhibit its activity, which could be a useful treatment for diseases where MIR1976 is over-expressed or too active.
In addition to these drugs, researchers are also exploring the potential of MIR1976 as a biomarker for a variety of diseases. By measuring the levels of MIR1976 in tissues or fluids, researchers can gain insights into the activity of the immune system and identify potential biomarkers for diseases.
One example of using MIR1976 as a biomarker is in the study of cancer. Researchers have shown that MIR1976 is often over-expressed in cancer tissues, and that inhibiting its activity could be a promising strategy for treating cancer. By measuring the levels of MIR1976 in cancer tissues, researchers can monitor the effectiveness of different treatments and identify potential biomarkers for the disease.
Another potential application of MIR1976 as a biomarker is in the study of fibrosis. Fibrosis is a condition in which tissues become stiff and inflamed, and can lead to a variety of diseases, including heart failure, lung disease, and kidney failure. Researchers have shown that MIR1976 is often over-expressed in fibrosis tissues, and that inhibiting its activity could be a promising strategy for treating this disease.
MIR1976 has also been shown to be involved in a number of other diseases and disorders, including autoimmune disorders, chronic obstructive pulmonary disease (COPD), and neurodegenerative diseases. As more research is done on MIR1976, it is likely that we will find even more potential applications for this protein as a drug target or biomarker.
In conclusion, MIR1976 is a protein that has the potential to be a drug target or biomarker in a variety of diseases. Its ability to interact with a wide range of different compounds makes it an attractive target for drug developers, and its role in the immune response and other diseases makes it an important molecule to study further. Further research is needed to fully understand the activity of MIR1976 and its potential as a drug or biomarker.
Protein Name: MicroRNA 1976
The "MIR1976 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1976 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074
